About: Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2
Creator	Corti, Davide Wang, David Ding, Siyuan Zhao, Haiyan Bloyet, Louis-Marie Diamond, Michael Amarasinghe, Gaya Case, James Fremont, Daved Sidhu, Sachdev Virgin, Herbert Whelan, Sean Kim, S Liu, Zhuoming Theel, Elitza Chen, Rita Droit, Lindsay Henderson, Jeffrey Ilagan, G Miersch, Shane Rothlauf, Paul Tahan, Stephen Tartell, Michael Ustav, Mart Xenia, Ma Zeng, Qiru
topic	covid:b8de9e9be00cfed1ff64c5c6dff807373120d7da#this
Source	BioRxiv; Medline
abstract	Antibody-based interventions against SARS-CoV-2 could limit morbidity, mortality, and possibly disrupt epidemic transmission. An anticipated correlate of such countermeasures is the level of neutralizing antibodies against the SARS-CoV-2 spike protein, yet there is no consensus as to which assay should be used for such measurements. Using an infectious molecular clone of vesicular stomatitis virus (VSV) that expresses eGFP as a marker of infection, we replaced the glycoprotein gene (G) with the spike protein of SARS-CoV-2 (VSV-eGFP-SARS-CoV-2) and developed a high-throughput imaging-based neutralization assay at biosafety level 2. We also developed a focus reduction neutralization test with a clinical isolate of SARS-CoV-2 at biosafety level 3. We compared the neutralizing activities of monoclonal and polyclonal antibody preparations, as well as ACE2-Fc soluble decoy protein in both assays and find an exceptionally high degree of concordance. The two assays will help define correlates of protection for antibody-based countermeasures including therapeutic antibodies, immune γ-globulin or plasma preparations, and vaccines against SARS-CoV-2. Replication-competent VSV-eGFP-SARS-CoV-2 provides a rapid assay for testing inhibitors of SARS-CoV-2 mediated entry that can be performed in 7.5 hours under reduced biosafety containment.
has issue date	2020-05-18(xsd:dateTime)
bibo:doi	10.1101/2020.05.18.102038
bibo:pmid	32511401
has license	biorxiv
sha1sum (hex)	b8de9e9be00cfed1ff64c5c6dff807373120d7da
schema:url	https://doi.org/10.1101/2020.05.18.102038
resource representing a document's title	Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2
has PubMed identifier	32511401
schema:publication	bioRxiv
resource representing a document's body	covid:b8de9e9be00cfed1ff64c5c6dff807373120d7da#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/b8de9e9be00cfed1ff64c5c6dff807373120d7da
is schema:about of	named entity 'morbidity' named entity 'polyclonal antibody' named entity 'compared' named entity 'spike' named entity 'LIMIT' named entity 'PLASMA' named entity 'CLINICAL ISOLATE' named entity 'NEUTRALIZATION TEST' covid:arg/b8de9e9be00cfed1ff64c5c6dff807373120d7da named entity 'soluble' named entity 'limit' named entity 'countermeasures' named entity 'neutralizing' named entity 'correlate' named entity 'high-throughput' named entity 'gene' named entity 'countermeasures' named entity 'correlates' named entity 'assays' named entity 'SARS-CoV-2' named entity 'biosafety' named entity 'developed' named entity 'neutralizing antibodies' named entity 'correlates of protection' named entity 'epidemic' named entity 'spike protein' named entity 'spike protein' named entity 'globulin' named entity 'neutralization test' named entity 'VSV' named entity 'high-throughput' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'VSV' named entity 'SARS-CoV-2' named entity 'viral vector' named entity 'antigen recognition' named entity 'SARS-CoV' named entity 'VSV' named entity 'ectodomain' named entity 'SARS-CoV-2' named entity 'SARS-CoV' named entity 'COVID' named entity 'mutation' named entity 'phosphorimaging' named entity 'inoculation' named entity 'glycoprotein' named entity 'nucleotide' named entity 'VSV' named entity 'BSL2' named entity 'protein' named entity 'endogenous' named entity 'protein' named entity 'Wuhan' named entity 'chimeric'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software